<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812383</url>
  </required_header>
  <id_info>
    <org_study_id>COBRA</org_study_id>
    <nct_id>NCT00812383</nct_id>
  </id_info>
  <brief_title>Carotid With Bivalirudin Angioplasty</brief_title>
  <acronym>COBRA</acronym>
  <official_title>Carotid With Bivalirudin Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <brief_summary>
    <textblock>
      Single center randomized clinical trial, to evaluate the safety and efficacy of carotid&#xD;
      artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic&#xD;
      Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System&#xD;
      using Angiomax (bivalirudin)versus heparin as the anticoagulant for treatment of occlusive&#xD;
      carotid artery disease in low and high risk patient cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2003</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate clinical success (&lt;50% residual stenosis at all treatment sites without death, myocardial infarction, stroke or major bleed)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess for complications including death, myocardial infarction, major or minor stroke, major or minor bleeding, and vascular complications.</measure>
    <time_frame>In hospital and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess stent patency , and occurence of death or recurrent neurological events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Carotid Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System</intervention_name>
    <description>Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be at least 18 years of age.&#xD;
&#xD;
          -  The patient must have a significant diameter reduction of the extracranial or&#xD;
             intracranial internal or common carotid artery, defined as ≥50% stenosis for&#xD;
             symptomatic patients or ≥80% stenosis for asymptomatic patients determined by carotid&#xD;
             duplex ultrasound scan and/or carotid angiography.&#xD;
&#xD;
          -  Female patients with child bearing potential must have a negative pregnancy test.&#xD;
&#xD;
          -  The patient and the patient's physician must agree to have the patient return for a&#xD;
             30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated&#xD;
             in the protocol.&#xD;
&#xD;
          -  Reference vessel diameter ≥ 3.5 mm - ≤ 9.0 mm diameter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has had a recent (&lt;4 weeks) disabling stroke or dementia with major&#xD;
             neurologic deficit (stroke scales: Barthel &lt;60, NIH &gt;15, or Rankin &gt;3) at&#xD;
             pre-procedure neuro exam.&#xD;
&#xD;
          -  The patient has had within four weeks of the treatment procedure an intracranial&#xD;
             hemorrhage, hemorrhage stroke, major stroke, or any stroke with mass effect&#xD;
             demonstrated on MRI or CT.&#xD;
&#xD;
          -  The patient has a known allergy to heparin, bivalirudin, aspirin or to anti-platelet&#xD;
             agents that prevents taking aspirin plus ticlopidine or aspirin plus clopidogrel.&#xD;
&#xD;
          -  The patient has received fractionated or unfractionated heparin within 8 hours prior&#xD;
             to the procedure.&#xD;
&#xD;
          -  The patient has a history of prior life-threatening radiocontrast reaction that cannot&#xD;
             be pre-treated.&#xD;
&#xD;
          -  The patient has a history of bleeding diathesis or coagulopathy within 3 months.&#xD;
&#xD;
          -  The patient is currently participating in another study protocol that may influence&#xD;
             either procedure results or follow-up evaluations.&#xD;
&#xD;
          -  Plasma/serum creatinine &gt; 3.0 mg/dl at time of intervention.&#xD;
&#xD;
          -  Hemodynamic instability at the time of intervention.&#xD;
&#xD;
          -  Previous stent placement in the ipsilateral carotid distribution.&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          -  The patient has an intracranial tumor, or cerebral arterio-venous malformation(s) &gt;&#xD;
             5mm, aneurysms or severe intracranial stenosis distal to target lesion.&#xD;
&#xD;
          -  The patient has inaccessible intracranial arterial stenosis greater in severity than&#xD;
             the extracranial internal carotid artery lesion.&#xD;
&#xD;
          -  There is angiographic evidence of significant intra-luminal thrombus burden with&#xD;
             presumed increased risk of plaque fragmentation and consequent distal embolization.&#xD;
&#xD;
          -  There is total occlusion of the ipsilateral carotid artery treatment site with TIMI 0&#xD;
             flow characteristics.&#xD;
&#xD;
          -  The reference segment diameter (internal carotid artery segment cephalad to the&#xD;
             lesion) is less than 3 millimeters by operator visual estimate.&#xD;
&#xD;
          -  The patient has peripheral vascular, supra-aortic or internal carotid artery&#xD;
             tortuosity precluding use of catheter-based techniques required for successful CSSA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lowell Satler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <disposition_first_submitted>October 22, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 28, 2020</disposition_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

